Carregant...
The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
ABP 215 (MVASI™, Amgen, Thousand Oaks, CA; MVASI™, Amgen Europe B.V., Netherlands) is a biosimilar to bevacizumab (Avastin(®), Genentech, South San Francisco, CA) reference product (RP), a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Here we provide a brief overview o...
Guardat en:
| Publicat a: | Oncol Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8140169/ https://ncbi.nlm.nih.gov/pubmed/33336310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-020-00133-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|